Logos next to one another 700x450.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

On-demand Webinar Series: Funding, Commercialisation and Market Access for Advanced Therapies

Phacilitate_BiotechandMoney_small.jpgLearn more about the key funding, commercialisation, and market access challenges facing advanced therapies in this three-part webinar seriesco-organised by Phacilitate and LSX (Formerly Biotech and Money)

The on-demand webinars are free to access, simply register below for dial-in details.  

 

Part one: Funding sources for advanced therapies 

The first webinar focuses on funding sources, and will feature Vamil Divan, Analyst at Credit Suisse, Dmitry Kuzmin, Managing Partner at 4BIO Capital, and Lucas de Breed, Director at INKEF Capital. The expert webinar panellists share their perspectives on the financing landscape for advanced therapies. The webinar also examines where and when to access capital to support long-term growth, and how companies can position themselves as an attractive investment opportunity.

  • Moderator: Vamil Divan, Analyst at Credit Suisse
  • Speaker: Dmitry Kuzmin, Managing Partner at 4BIO Capital
  • Speaker: Lucas de Breed, Director at INKEF Capital
  • Now available on demand: Listen here

Part two: Tackling the scale-up challenge and the role of tech innovation and finance 

This webinar looks at the barriers to commercialising advanced therapies, including overcoming scale-up obstacles and the impact that the right investor can have on commercialisation. In addition, Rodney Rietze, Senior Investigator, Exploratory Immuno-Oncology Group at Novartis Institute for Biomedical Research, discusses the lifecycle of an automation project, how to develop a robust automation strategy, and how to ensure your capital delivers the anticipated return on investment. Ron Philip, Head of Global Commercial at Spark Therapeutics, explores the challenges of commercialising a novel, one-time treatment for an ultra-rare disease. 

  • Moderator: Duncan Mackay, Head of Regulatory Affairs at ERA Consulting
  • Speaker: Rodney Rietze, Senior Investigator, Exploratory Immuno-Oncology Group at Novartis Institute for Biomedical Research
  • Speaker: Ron Philip, Head of Global Commercial at Spark Therapeutics
  • Speaker: Gbola Amusa, Partner, Director of Research, and Head of Healthcare Research at Chardan 
  • Speaker: Anna French, Associate at Qiming Venture Partners
  • Now available on demand: Listen here

Part three: Gaining market access in a challenging European environment 

The third and final webinar in the series covers market access, pricing and reimbursement for advanced therapies.

  • Moderator: Graham Tatham, Director at Simon-Kucher & Partners
  • Speaker: Thomas Lönngren, Strategic Advisor at NDA Group
  • Speaker: Panos Kefalas, Head of Health Economics and Market Access at Cell and Gene Therapy Catapult
  • Now available on demand: Listen here

 

Learn more from industry leaders at Phacilitate Leaders Europe. The event will bring the whole advanced therapies ecosystem together in London on 11-12 September 2018. Qualified investors can register for free here

 

Feature image © bluebay2014 – stock.adobe.com 

LSX
Written By

Add Your Response